AbbVie (ABBV) Research & Development (2012 - 2026)
AbbVie's Research & Development was $2.57 billion in Q3 2026, up 10.7% from $2.32 billion a year earlier and up 9.5% from the prior quarter.
Powered by 
Analysis
AbbVie (ABBV) Research & Development (2012 - 2026) Analysis & Trends
On a trailing twelve-month basis, AbbVie's Research & Development was $9.96 billion through Sep 30, 2026, down 25.0% year-over-year; for FY2025, it was $9.1 billion, down 28.9% from FY2024.
- Research & Development shows a five-year compound annual growth rate of 7.4% (FY2020 to FY2025).
- In earlier years, Research & Development was $12.79 billion in FY2024 (+66.7%), $7.68 billion in FY2023 (+17.9%), $6.51 billion in FY2022 (-6.0%) and $6.92 billion in FY2021 (+8.5%).
- Quarterly Research & Development has moved between $1.5 billion (Q1 2022) and $6.77 billion (Q4 2024) over five years.
- Compared with a year earlier, Research & Development has increased for three straight quarters, with growth averaging 31.8% over the last eight quarters.
- The best year-over-year quarter for Research & Development over five years was Q4 2024 (growth of 251.5%); the worst was Q4 2025 (a decline of 61.9%).
- Per Business Quant data, ABBV's Research & Development in the three quarters before Q3 2026 was $2.34 billion (Q2 2026), $2.47 billion (Q1 2026) and $2.58 billion (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,264.65 Bn | 1,238.27 Bn | 20.46 Bn | 4.25 Bn |
| 2 | Johnson & Johnson | 677.74 Bn | 597.60 Bn | 17.30 Bn | 4.65 Bn |
| 3 | AbbVie | 517.10 Bn | 485.11 Bn | 13.12 Bn | 2.57 Bn |
| 4 | Merck | 362.23 Bn | 325.17 Bn | 13.19 Bn | 4.54 Bn |
| 5 | Novartis Ag | 315.90 Bn | 276.16 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 289.40 Bn | 266.24 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 249.90 Bn | 201.56 Bn | 7.58 Bn | 2.11 Bn |
| 8 | Gilead Sciences | 209.15 Bn | 184.26 Bn | 6.73 Bn | 1.61 Bn |
| 9 | Pfizer | 165.88 Bn | 113.23 Bn | 12.56 Bn | 3.02 Bn |
| 10 | Vertex Pharmaceuticals | 138.78 Bn | 110.77 Bn | 2.91 Bn | 1.32 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 2.57 Bn |
| Jun 30, 2026 | 2.34 Bn |
| Mar 31, 2026 | 2.47 Bn |
| Dec 31, 2025 | 2.58 Bn |
| Sep 30, 2025 | 2.32 Bn |
| Jun 30, 2025 | 2.13 Bn |
| Mar 31, 2025 | 2.07 Bn |
| Dec 31, 2024 | 6.77 Bn |
| Sep 30, 2024 | 2.13 Bn |
| Jun 30, 2024 | 1.95 Bn |
| Mar 31, 2024 | 1.94 Bn |
| Dec 31, 2023 | 1.93 Bn |
| Sep 30, 2023 | 1.72 Bn |
| Jun 30, 2023 | 1.73 Bn |
| Mar 31, 2023 | 2.29 Bn |
| Dec 31, 2022 | 1.79 Bn |
| Sep 30, 2022 | 1.61 Bn |
| Jun 30, 2022 | 1.61 Bn |
| Mar 31, 2022 | 1.50 Bn |
| Dec 31, 2021 | 1.83 Bn |
API Access
AbbVie Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=ABBV&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "ABBV", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=ABBV&period=max&api_key=YOUR_API_KEY");
const data = await res.json();